<DOC>
	<DOCNO>NCT01667120</DOCNO>
	<brief_summary>The general purpose study characterize safety profile ketorolac infant age 0-3 month . Our hypothesis ketorolac safe neonate , effective control pain le narcotic administration require . Ketorolac 0.5mg/kg intravenously every 8 hr 72hrs administer versus equivalent volume 0.9 % normal saline placebo . Primary : The primary purpose study compare bleed event neonate receive ketorolac receive ketorolac . The investigator hypothesize ketorolac safe effective infant &gt; 37wks gestation least one week age . Secondary : The investigator intend evaluate daily creatinine level , pain score , urine output per shift , platelet count , hemoglobin level , number day ventilator , amount narcotic administer , blood pressure , reintubation event patient study secondary study point .</brief_summary>
	<brief_title>The Use Ketorolac Surgical Neonates</brief_title>
	<detailed_description>This Phase II , single center , randomize control pilot study . Hospitalized patient one week age 3 month age undergo abdominal surgical procedure within moderate severe degree pain category ( see attach Table 1 : postoperative pain category ) randomize receive standard pain management regimens plus placebo ( 0.9 % saline equivalent volume ) ketorolac 0.5mg IV q8h x 72h plus standard pain management regimen . The postoperative management unchanged discretion attend surgeon , appropriate surgical procedure . The patient follow 5 day , 48hrs end ketorolac therapy primary secondary endpoint .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>1 . Infants gestational age &gt; 37 week great equal one week age 3 month age 2 . Infants undergo surgical procedure abdomen 3. parent guardian give informed consent . 1 . Gestational age &lt; 37 week 2 . Age le one week great 3 month age 3 . Known renal disease/dysplastic kidney 4 . Serum Creatinine &gt; 0.4 5 . Patients rise creatinine level day prior surgery ( increase least 1.5fold baseline ) 6 . Patients currently receive potentially renal toxic drug drug may interfere hemostatic pathway part clinical care ( include limit furosemide , hydrochlorothiazide , vancomycin , gentamicin , aspirin , tpa [ except use thrombosed central venous catheter ] , enalapril , systemic heparin [ except use central venous catheter flush ] ) 7 . Patients undergo nephrectomy 8 . Patients necrotizing enterocolitis 9 . Patients hemoglobin value &lt; 10g/dL 10 . Recent ( within 3 month ) GI bleeding , ulceration , and/or perforation 11 . Platelet count &lt; 50,000 12 . Ongoing disseminate intravascular coagulation history intraventricular hemorrhage 13 . Recent ( within 2 week ) use current use nonsteroidal antiinflammatory drug ( NSAIDS ) besides aspirin ( ASA ) 14 . Allergy ASA NSAIDS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ketorolac</keyword>
	<keyword>postoperative pain</keyword>
	<keyword>bleed event</keyword>
</DOC>